Search Results - "Kanerva, Anna"

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment by Hemminki, Kari, Kanerva, Anna, Försti, Asta, Hemminki, Akseli

“…Incidence of cervical cancer has been reduced by organized screening while for vaginal and vulvar cancers no systematic screening has been implemented. All…”
Get full text

The impact of tree crops and temperature on the timing of frugivorous bird migration by Kanerva, Anna-Maria, Hokkanen, Tatu, Lehikoinen, Aleksi, Norrdahl, Kai, Suhonen, Jukka

“…Migration has evolved to tackle temporal changes in availability of resources. Climate change has been shown to affect the migration dates of species, which…”
Get full text

Familial risks of ovarian cancer by age at diagnosis, proband type and histology by Zheng, Guoqiao, Yu, Hongyao, Kanerva, Anna, Försti, Asta, Sundquist, Kristina, Hemminki, Kari

“…Ovarian cancer is a heterogeneous disease. Data regarding familial risks for specific proband, age at diagnosis and histology are limited. Such data can assist…”
Get full text

Familial Ovarian Cancer Clusters with Other Cancers by Zheng, Guoqiao, Yu, Hongyao, Kanerva, Anna, Försti, Asta, Sundquist, Kristina, Hemminki, Kari

“…Familial risk of ovarian cancer is well-established but whether ovarian cancer clusters with other cancers and the clusters differ by histology remains…”
Get full text

Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus by DIACONU, Lulia, CERULLO, Vincenzo, ELIOPOULOS, Aristides G, PESONEN, Sari, HEMMINKI, Akseli, HIRVINEN, Mari L. M, ESCUTENAIRE, Sophie, UGOLINI, Matteo, PESONEN, Saila K, BRAMANTE, Simona, PARVIAINEN, Suvi, KANERVA, Anna, LOSKOG, Angelica S. I

“…Oncolytic adenovirus is an attractive platform for immunotherapy because virus replication is highly immunogenic and not subject to tolerance. Although…”
Get full text

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control by Quixabeira, Dafne C. A., Zafar, Sadia, Santos, Joao M., Cervera-Carrascon, Victor, Havunen, Riikka, Kudling, Tatiana V., Basnet, Saru, Anttila, Marjukka, Kanerva, Anna, Hemminki, Akseli

“…The notion of developing variants of the classic interleukin 2 (IL-2) cytokine has emerged from the limitations observed with the systemic use of human IL-2 in…”
Get full text

Correction: Familial risks of ovarian cancer by age at diagnosis, proband type and histology by Zheng, Guoqiao, Yu, Hongyao, Kanerva, Anna, Försti, Asta, Sundquist, Kristina, Hemminki, Kari

“…[This corrects the article DOI: 10.1371/journal.pone.0205000.]…”
Get full text

An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor Clearance by Cerullo, Vincenzo, Diaconu, Iulia, Romano, Valentina, Hirvinen, Mari, Ugolini, Matteo, Escutenaire, Sophie, Holm, Sirkka-Liisa, Kipar, Anja, Kanerva, Anna, Hemminki, Akseli

“…Oncolytic viruses represent a multifaceted tool for cancer treatment. In addition to specific killing of cancer cells (oncolysis), these agents also provide…”
Get full text

Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients by CERULLO, Vincenzo, PESONEN, Sari, RAJECKI, Maria, KANGASNIEMI, Lotta, GUSE, Kilian, HELMINEN, Andreas, AHTIAINEN, Laura, RISTIMÄKI, Ari, RÄISÄNEN-SOKOLOWSKI, Anne, HAAVISTO, Elina, OKSANEN, Minna, KARLI, Eerika, DIACONU, Lulia, KARIOJA-KALLIO, Aila, HOLM, Sirkka-Liisa, KOURI, Mauri, JOENSUU, Timo, KANERVA, Anna, HEMMINKI, Akseli, ESCUTENAIRE, Sophie, ARSTILA, Petteri T, UGOLINI, Matteo, NOKISALMI, Petri, RAKI, Mari, LAASONEN, Leena, SÄRKIOJA, Merja

“…Granulocyte macrophage colony-stimulating factor (GMCSF) can mediate antitumor effects by recruiting natural killer cells and by induction of tumor-specific…”
Get full text

Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors by Tähtinen, Siri, Kaikkonen, Saija, Merisalo-Soikkeli, Maiju, Grönberg-Vähä-Koskela, Susanna, Kanerva, Anna, Parviainen, Suvi, Vähä-Koskela, Markus, Hemminki, Akseli

“…Unfavorable ratios between the number and activation status of effector and suppressor immune cells infiltrating the tumor contribute to resistance of solid…”
Get full text

TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling by Heiniö, Camilla, Havunen, Riikka, Santos, Joao, de Lint, Klaas, Cervera-Carrascon, Victor, Kanerva, Anna, Hemminki, Akseli

“…In order to break tumor resistance towards traditional treatments, we investigate the response of tumor and immune cells to a novel, cytokine-armed oncolytic…”
Get full text

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression by Kudling, Tatiana V., Clubb, James H.A., Quixabeira, Dafne C.A., Santos, Joao M., Havunen, Riikka, Kononov, Alexander, Heiniö, Camilla, Cervera-Carrascon, Victor, Pakola, Santeri, Basnet, Saru, Grönberg-Vähä-Koskela, Susanna, Arias, Victor, Gladwyn-Ng, Ivan, Aro, Katri, Bäck, Leif, Räsänen, Jari, Ilonen, Ilkka, Borenius, Kristian, Räsänen, Mikko, Hemminki, Otto, Rannikko, Antti, Kanerva, Anna, Tapper, Johanna, Hemminki, Akseli

“…Cytokines have proven to be effective for cancer therapy, however whilst low-dose monotherapy with cytokines provides limited therapeutic benefit, high-dose…”
Get full text

Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues by Koski, Anniina, Bramante, Simona, Kipar, Anja, Oksanen, Minna, Juhila, Juuso, Vassilev, Lotta, Joensuu, Timo, Kanerva, Anna, Hemminki, Akseli

“…In clinical trials with oncolytic adenoviruses, there has been no mortality associated with treatment vectors. Likewise, in the Advanced Therapy Access Program…”
Get full text

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1 by Quixabeira, Dafne C. A., Cervera-Carrascon, Victor, Santos, Joao M., Clubb, James H.A., Kudling, Tatiana V., Basnet, Saru, Heiniö, Camilla, Grönberg-Vähä-Koskela, Susanna, Anttila, Marjukka, Havunen, Riikka, Kanerva, Anna, Hemminki, Akseli

“…Intratumoral immunotherapies are entering clinical use but concerns remain regarding their effects on non-injected tumors. Here, we studied the impact of local…”
Get full text

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity by Santos, João Manuel, Heiniö, Camilla, Cervera-Carrascon, Victor, Quixabeira, Dafne C A, Siurala, Mikko, Havunen, Riikka, Butzow, Ralf, Zafar, Sadia, de Gruijl, Tanja, Lassus, Heini, Kanerva, Anna, Hemminki, Akseli

“…BackgroundOvarian cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy…”
Get full text

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy by Havunen, Riikka, Siurala, Mikko, Sorsa, Suvi, Grönberg-Vähä-Koskela, Susanna, Behr, Michael, Tähtinen, Siri, Santos, João Manuel, Karell, Pauliina, Rusanen, Juuso, Nettelbeck, Dirk M., Ehrhardt, Anja, Kanerva, Anna, Hemminki, Akseli

“…Adoptive cell therapy holds much promise in the treatment of cancer but results in solid tumors have been modest. The notable exception is tumor-infiltrating…”
Get full text

Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1 by Cervera-Carrascon, Victor, Quixabeira, Dafne C A, Santos, Joao M, Havunen, Riikka, Milenova, Ioanna, Verhoeff, Jan, Heiniö, Camilla, Zafar, Sadia, Garcia-Vallejo, Juan J, van Beusechem, Victor W, de Gruijl, Tanja D, Kalervo, Aino, Sorsa, Suvi, Kanerva, Anna, Hemminki, Akseli

“…Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not…”
Get full text

Modified adenoviruses for cancer gene therapy by Kanerva, Anna, Hemminki, Akseli

“…Adenoviral gene therapy is an exciting novel approach for treating cancers resistant to currently available therapies. However, currently there is little…”
Get full text

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus by Havunen, Riikka, Santos, João M., Sorsa, Suvi, Rantapero, Tommi, Lumen, Dave, Siurala, Mikko, Airaksinen, Anu J., Cervera-Carrascon, Victor, Tähtinen, Siri, Kanerva, Anna, Hemminki, Akseli

“…Cancer treatment with local administration of armed oncolytic viruses could potentially induce systemic antitumor effects, or the abscopal effect, as they…”
Get full text

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors by Jirovec, Elise, Quixabeira, Dafne C. A, Clubb, James H. A, Pakola, Santeri A, Kudling, Tatiana, Arias, Victor, Haybout, Lyna, Jalkanen, Katriina, Alanko, Tuomo, Monberg, Tine, Khammari, Amir, Dreno, Brigitte, Svane, Inge Marie, Block, Matthew S, Adamo, Daniel A, Mäenpää, Johanna, Kistler, Claudia, Sorsa, Suvi, Hemminki, Otto, Kanerva, Anna, Santos, João M, Cervera-Carrascon, Victor, Hemminki, Akseli

“…Abstract Background A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec,…”
Get full text